South African scientists have identified two new breast cancer genes -- RAB27A and USP22 -- in Black women, marking the first GWAS of its kind on the continent. This breakthrough highlights the need ...

Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

An exciting new treatment approach for aggressive breast cancers significantly improves survival rates for patients ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

Overall survival (OS) in BRCA -mutated breast cancer improved significantly with the addition of olaparib (Lynparza) to ...

In neighborhoods across America, women face a daunting threat from a federal practice that, although it was outlawed decades ago, continues to negatively impact their health today.

New research indicates that while the residential segregation policy was outlawed decades ago, it still impacts women's health today.

The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.

By adding the newly identified genes to previously known breast cancer genes like BRCA1 and BRCA2, the researchers developed ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

LTRN A May 5 th  press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer ...